Pacira BioSciences, Inc. Common Stock (PCRX)

Price$24.90

Favorite Metrics

Price vs S&P 500 (26W)1.86%

Price vs S&P 500 (4W)2.31%

Market Capitalization$1.00B

P/E Ratio (Annual)142.30x

All Metrics

P/CF (Annual)6.59x

Book Value / Share (Quarterly)$16.86

P/TBV (Annual)3.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.90%

Cash Flow / Share (Quarterly)$3.32

Price vs S&P 500 (YTD)-8.62%

Gross Margin (TTM)79.39%

Net Profit Margin (TTM)0.97%

EPS (TTM)$0.16

10-Day Avg Trading Volume0.44M

EPS Excl Extra (TTM)$0.16

Revenue Growth (5Y)11.08%

EPS (Annual)$0.16

ROI (Annual)0.66%

Gross Margin (Annual)79.39%

Net Profit Margin (5Y Avg)0.63%

Cash / Share (Quarterly)$5.80

P/E Basic Excl Extra (TTM)142.30x

Revenue Growth QoQ (YoY)5.14%

EPS Growth (5Y)-45.77%

P/E Normalized (Annual)142.30x

ROA (Last FY)0.56%

Revenue Growth TTM (YoY)3.63%

EBITD / Share (TTM)$1.54

ROE (5Y Avg)0.17%

Operating Margin (TTM)0.99%

Cash Flow / Share (Annual)$3.32

P/B Ratio1.44x

P/B Ratio (Quarterly)1.61x

Net Income / Employee (Annual)$0

EV / Revenue (TTM)1.67x

Net Interest Coverage (TTM)7.96x

ROA (TTM)0.49%

EPS Growth QoQ (YoY)-89.03%

EV / EBITDA (TTM)17.63x

EPS Incl Extra (Annual)$0.16

Current Ratio (Annual)4.54x

Quick Ratio (Quarterly)3.01x

3-Month Avg Trading Volume0.85M

52-Week Price Return1.02%

EV / Free Cash Flow (Annual)8.89x

P/E Incl Extra (TTM)142.30x

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$7.90

P/S Ratio (Annual)1.38x

Asset Turnover (Annual)0.57x

52-Week High$27.64

Operating Margin (5Y Avg)5.54%

EPS Excl Extra (Annual)$0.16

CapEx CAGR (5Y)-16.51%

Tangible BV CAGR (5Y)-9.08%

26-Week Price Return10.60%

Quick Ratio (Annual)3.01x

13-Week Price Return11.15%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)4.54x

Enterprise Value$1,214.554

Revenue / Share Growth (5Y)10.41%

Asset Turnover (TTM)0.51x

Book Value / Share Growth (5Y)3.47%

Revenue / Employee (Annual)$1

Inventory Turnover (Annual)1.08x

Pretax Margin (Annual)2.32%

Cash / Share (Annual)$5.80

3-Month Return Std Dev40.27%

Gross Margin (5Y Avg)74.39%

Net Income / Employee (TTM)$0

EBITDA CAGR (5Y)7.05%

EBITDA Interim CAGR (5Y)-4.81%

ROE (Last FY)1.01%

Net Interest Coverage (Annual)1.36x

EPS Basic Excl Extra (Annual)$0.16

P/FCF (TTM)7.32x

Receivables Turnover (TTM)6.12x

EV / Free Cash Flow (TTM)8.89x

Total Debt / Equity (Quarterly)0.54x

EPS Incl Extra (TTM)$0.16

Receivables Turnover (Annual)6.12x

ROI (TTM)0.58%

P/S Ratio (TTM)1.38x

Pretax Margin (5Y Avg)2.97%

Revenue / Share (Annual)$16.13

Tangible BV / Share (Annual)$7.90

Forward P/E9.49x

Free OCF CAGR (5Y)28.37%

Price vs S&P 500 (52W)-34.07%

P/E Ratio (TTM)142.30x

Year-to-Date Return-4.48%

5-Day Price Return2.74%

EPS Normalized (Annual)$0.16

ROA (5Y Avg)-0.04%

Net Profit Margin (Annual)0.97%

Month-to-Date Return9.38%

Cash Flow / Share (TTM)$1.93

EBITD / Share (Annual)$1.53

EPS Growth (3Y)-22.98%

Operating Margin (Annual)0.99%

LT Debt / Equity (Annual)0.54x

P/CF (TTM)6.59x

ROI (5Y Avg)-0.04%

P/E Excl Extra (TTM)142.30x

LT Debt / Equity (Quarterly)0.54x

EPS Basic Excl Extra (TTM)$0.16

P/TBV (Quarterly)3.43x

P/B Ratio (Annual)1.61x

Inventory Turnover (TTM)1.08x

Pretax Margin (TTM)2.32%

Book Value / Share (Annual)$16.86

Price vs S&P 500 (13W)8.29%

Net Margin Growth (5Y)-50.86%

Beta0.28x

P/FCF (Annual)7.32x

Revenue / Share (TTM)$16.90

ROE (TTM)0.95%

52-Week Low$18.80

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.85

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PCRXPacira BioSciences, Inc. Common Stock	1.38x	3.63%	79.39%	-45.77%	$24.90
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Pacira BioSciences develops and commercializes non-opioid pain management and regenerative health solutions. The company's marketed products include EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis, and iovera, a handheld device providing drug-free pain relief through controlled cold therapy. Pacira is also advancing PCRX-201, a gene therapy candidate for knee osteoarthritis.